97-13022. Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 62, Number 96 (Monday, May 19, 1997)]
    [Notices]
    [Pages 27261-27262]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-13022]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). The meeting will 
    be open to the public.
        Name of Committee: Antiviral Drugs Advisory Committee.
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA regulatory issues.
        Date and Time: The meeting will be held on July 14 and 15, 1997, 
    8:30 a.m. to 5 p.m..
        Location: Armory Place, rm. 204, 925 Wayne Ave., Silver Spring, MD.
        Contact Person: Rhonda W. Stover or John B. Schupp, Center for Drug 
    Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
    Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory 
    Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
    Washington, DC area), code 12531. Please call the Information Line for 
    up-to-date information on this meeting.
        Agenda: On July 14 and 15, 1997, the committee will discuss the 
    utility of plasma human immunodeficiency virus (HIV) RNA measurement as 
    an endpoint in clinical trials for drugs to treat HIV infection. In 
    light of the rapid changes
    
    [[Page 27262]]
    
    in knowledge about the pathophysiology of HIV infection, the advances 
    in the technologies to quantify HIV in plasma and the evolution of 
    antiviral therapy, FDA is soliciting opinions and advice from the 
    advisory committee on this topic.
        Procedure: Interested persons may present data, information, or 
    views, orally or in writing, on issues pending before the committee. 
    Written submissions may be made to the contact person by July 7, 1997. 
    Oral presentations from the public will be scheduled on July 14, 1997, 
    between approximately 11 a.m. to 12 m. Time allotted for each 
    presentation may be limited. Those desiring to make formal oral 
    presentations should notify the contact person before July 7, 1997, and 
    submit a brief statement of the general nature of the evidence or 
    arguments they wish to present, the names and addresses of proposed 
    participants, and an indication of the approximate time requested to 
    make their presentation.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: May 13, 1997.
    Michael A. Friedman,
    Deputy Commissioner for Operations.
    [FR Doc. 97-13022 Filed 5-16-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
05/19/1997
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
97-13022
Pages:
27261-27262 (2 pages)
PDF File:
97-13022.pdf